InLight Medical

Executive Summary

InLight Medical (Inlight Therapy) is a San Diego-based medical device company specializing in photobiomodulation (PBM) therapy systems using light-emitting diodes (LEDs). Its FDA Class II cleared devices target pain relief, inflammation reduction, and tissue regeneration for both professional and home use. The company addresses a large and growing market for non-invasive pain management, competing with traditional pharmaceuticals and other physical modalities. By leveraging LED technology, InLight offers cost-effective, drug-free solutions that can be used repeatedly without side effects. The company's product portfolio includes wearable and handheld devices designed for conditions such as arthritis, neuropathy, and musculoskeletal pain. With a founding year of 2015, InLight has navigated FDA clearance pathways and likely established initial commercial traction, though specific revenue and funding details are not publicly disclosed. InLight Medical operates in an expanding market driven by opioid crisis concerns and increasing demand for non-pharmacological pain alternatives. The company's competitive advantage lies in its proprietary LED wavelength and dosing protocols. Upcoming catalysts include potential new FDA 510(k) clearances for expanded indications (e.g., chronic low back pain), which could unlock larger market segments. Additionally, clinical study publications demonstrating efficacy would build clinical evidence and support insurance reimbursement. Strategic partnerships with physical therapy chains or sports medicine clinics could accelerate adoption. The company's private status suggests that any future funding round or acquisition interest may serve as a catalyst for visibility and growth. Overall, InLight Medical is well-positioned in the photobiomodulation space but faces competition from other PBM device companies and conservative reimbursement landscapes.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for new chronic pain indication70% success
• Q4 2026Publication of pivotal clinical trial results in peer-reviewed journal60% success
• TBDDistribution partnership with a national healthcare provider50% success